

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1 (Master Protocol); 1 (PREVESTATGx Trial Protocol)
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	1 (Master Protocol); 1 (PREVESTATGx Trial Protocol)
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	1 (Master Protocol); 1 (PREVESTATGx Trial Protocol)
Protocol version	#3	Date and version identifier	1 (Master Protocol); 1 (PREVESTATGx Trial Protocol)
Funding	#4	Sources and types of financial, material, and other support	(Master Protocol) 3

Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	(Master Protocol) 18
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	13 (Master Protocol)
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	16 (Master Protocol) Specified in the submitted manuscript
Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	(Master Protocol) 16

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	13 (Master Protocol); 15 (PREVESTATGx Trial Protocol)
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	19 (Master Protocol); 12 (PREVESTATGx Trial Protocol)
Objectives	#7	Specific objectives or hypotheses	15 (Master Protocol); 19 (PREVESTATGx Trial Protocol)
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover,	3 (Master Protocol); 14 (PREVESTATGx Trial Protocol)

factorial, single group), allocation ratio, Protocol)
 and framework (eg, superiority,
 equivalence, non-inferiority, exploratory)

**Methods:
 Participants,
 interventions, and
 outcomes**

Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	13,14 (PREVESTAT Trial Protocol)
Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	21,22 (PREVESTAT Trial Protocol)
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	23;41-44 (PREVESTAT Trial Protocol)
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	24,34 (PREVESTAT Trial Protocol)
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	26 (Master Protocol)
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	25 (Master Protocol) 23 (PREVESTATGx Trial Protocol)
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	19-21;28,34 (PREVESTATGx Trial Protocol)

pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	10 (PREVESTATGx Trial Protocol)
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	9, 28 (PREVESTATGx Trial Protocol)
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	13 (submitted manuscript)

**Methods:
Assignment of
interventions (for
controlled trials)**

Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	31 (PREVESTATGx Trial Protocol)
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing	31 (PREVESTATGx Trial Protocol)

any steps to conceal the sequence until interventions are assigned

Allocation: implementation [#16c](#) Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 31 (PREVESTATGx Trial Protocol)

Blinding (masking) [#17a](#) Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 31 (PREVESTATGx Trial Protocol)

Blinding (masking): emergency unblinding [#17b](#) If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial 31 (PREVESTATGx Trial Protocol)

Methods: Data collection, management, and analysis

Data collection plan [#18a](#) Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 16 (Master Protocol)
20, 21, 28 (PREVESTATGx Trial Protocol)

Data collection plan: retention [#18b](#) Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols 23 (Master Protocol)

Data management [#19](#) Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg,

double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol

Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	34 (PREVESTATGx Trial Protocol)
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	34 (PREVESTATGx Trial Protocol)
Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	34 (PREVESTATGx Trial Protocol)

Methods: Monitoring

Data monitoring: formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	16 (Master Protocol)
Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	24, 28, 29 (PREVESTATGx Trial)
Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	37 (Master Protocol) 32 (PREVESTATGx)

Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	27 (Master Protocol)
Ethics and dissemination			
Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	30 (Master Protocol)
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	40 (PREVESTATGx)
Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	31 (Master Protocol)
Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	10, 46 (PREVESTATGx)
Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	31 (Master Protocol)
Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	N/A. None of the PIs have competing or financial interests for the overall trial as this is funded through a public grant.
Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such	31 (PREVESTATGx)

access for investigators

Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A This is a Phase IV performed following standard clinical practice with authorised drugs. No harm excess is anticipated when compared to standard population.
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	40 (Master Protocol)
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	40 (Master Protocol)
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	40 (Master Protocol)

Appendices

Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	Informed consent forms are found in separate documents and consist of adult consent exclusively
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	40-47 (PREVESTATGx Trial Protocol)

None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)